In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Dexcom Inc (NASDAQ: DXCM) closed at $134.30 up 0.33% from its previous closing price of $133.86. In other words, the price has increased by $0.33 from its previous closing price. On the day, 2.12 million shares were traded. DXCM stock price reached its highest trading level at $135.9833 during the session, while it also had its lowest trading level at $133.58.
Ratios:
For a deeper understanding of Dexcom Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 19.01 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 101.14. For the most recent quarter (mrq), Quick Ratio is recorded 2.48 and its Current Ratio is at 2.84. In the meantime, Its Debt-to-Equity ratio is 1.25 whereas as Long-Term Debt/Eq ratio is at 1.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on March 12, 2024, initiated with a Outperform rating and assigned the stock a target price of $165.
Raymond James Upgraded its Outperform to Strong Buy on April 17, 2023, whereas the target price for the stock was revised from $127 to $138.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 15 ’24 when Dolan Matthew Vincent sold 1,990 shares for $137.81 per share. The transaction valued at 274,242 led to the insider holds 42,377 shares of the business.
SAYER KEVIN R sold 49,633 shares of DXCM for $6,864,136 on Apr 08 ’24. The President CEO and Chairman now owns 283,893 shares after completing the transaction at $138.30 per share. On Mar 28 ’24, another insider, Brown Michael Jon, who serves as the EVP Chief Legal Officer of the company, sold 2,624 shares for $140.04 each. As a result, the insider received 367,472 and left with 68,682 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DXCM now has a Market Capitalization of 51774664704 and an Enterprise Value of 51644620800. As of this moment, Dexcom’s Price-to-Earnings (P/E) ratio for their current fiscal year is 102.46, and their Forward P/E ratio for the next fiscal year is 60.03. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.07. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.29 while its Price-to-Book (P/B) ratio in mrq is 25.02. Its current Enterprise Value per Revenue stands at 14.257 whereas that against EBITDA is 65.898.
Stock Price History:
Over the past 52 weeks, DXCM has reached a high of $142.00, while it has fallen to a 52-week low of $74.75. The 50-Day Moving Average of the stock is 4.01%, while the 200-Day Moving Average is calculated to be 16.82%.
Shares Statistics:
For the past three months, DXCM has traded an average of 3.07M shares per day and 2474800 over the past ten days. A total of 385.40M shares are outstanding, with a floating share count of 377.37M. Insiders hold about 2.11% of the company’s shares, while institutions hold 98.96% stake in the company. Shares short for DXCM as of 1711584000 were 14572039 with a Short Ratio of 4.74, compared to 1709164800 on 16648248. Therefore, it implies a Short% of Shares Outstanding of 14572039 and a Short% of Float of 4.279999999999999.
Earnings Estimates
The stock of Dexcom Inc (DXCM) is currently being evaluated by DXC Technology Company analysts who are actively contributing to its market rating.
